Tous Actualités
Suivre
Abonner SYGNIS AG

SYGNIS AG

EANS-News: Sygnis Pharma AG proposes reduction of share capital to improve flexibility on capital markets

Heidelberg (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Annual & Special Corporate Meetings
Press Release
Heidelberg,  October  20,  2010  -  SYGNIS  Pharma  AG  (Frankfurt:  
LIO;   ISIN DE0005043509; Prime Standard),  a  clinical  stage  
biotech  company  developing innovative CNS treatments, invited 
shareholders to its  Annual  General  Meeting for financial year 2009
/ 2010 on November 30, 2010.  At the meeting  the  Board will propose
a reduction of the Company´s share capital according to §§ 222  ff. 
German Stock Corporation Act (AktG).
This reduction will be combined with a consolidation of  the  shares 
in  a  3:1 ratio. As a result, the share capital will be reduced from
EUR  41,258,643  to EUR 13,752,881, allocated to 13,752,881 shares 
outstanding.
The purpose of this process is primarily to improve the Company´s  
abilities  to interact on the capital markets. The planned measure is
based on the  fact  that the Company´s share price has been below the
nominal value of EUR 1 for  a longer period. Following the capital 
reduction and consolidation of shares,  the  share price is expected 
to increase significantly to a level above the nominal  value.
The SYGNIS share will thus comply with the relevant requirements and 
will be more attractive for investors. Furthermore, the planned 
measure will improve the flexibility of the company for future 
capital measures and the development of financing alternatives. The 
released capital will be used for the reduction of losses.
As of June 30, 2010 the liquidity of the company was EUR13.1 million.
About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg, is
a  biopharmaceutical  company listed on the Prime Standard of  the  
German  stock  exchange.  The  Company  is focused on the research, 
development and marketing of innovative  therapies  for the treatment
of disorders of the Central Nervous System. These  include  stroke 
and various forms of dementia. These disorders are characterized by 
an acute  or gradual loss of nerve cells, which for the patients 
always means  a  decline  of functional  abilities.  Although  there 
is  great  medical  demand,  there  are currently no or only 
inadequate treatment options available.
One of the central  elements  in  the  Company´s  value-creation  
chain  is  the continued development of the existing product  
pipeline.  This  is  achieved  by
testing  the  Company´s  proprietary  compounds,   which   are   already   under
development in  a  number  of  further  CNS  indications.  Within  specific  R&D
programs  at  SYGNIS,  new  pre-clinical  drug  candidates  are  identified  and
evaluated as well as early-stage projects  are  initiated  for  the  purpose  of
partnering.
Disclaimer Some statements included in this  press  release,  
relating  neither  to  proven financial results nor other  historical
data,  should  be  viewed  as  forward- looking, i.e. not definite. 
Such statements are  mainly  predictions  of  future results, trends,
plans or goals. These statements should not  be  considered  to be 
total guarantees since given their very nature they are subject to 
known  and unknown risks and imponderability and can be affected  by 
other  factors  as  a consequence of which the actual results, plans 
and goals  of  SYGNIS  Pharma  AG may deviate greatly from the  
established  conclusions  or  implied  predictions contained in such 
statements. SYGNIS does not undertake to  publicly  update  or revise
these statements in the light of new information  or  future  results
or for any other reason. ###
end of announcement                               euro adhoc

Further inquiry note:

For further information please contact:
SYGNIS Pharma AG:
Dr. Franz-Werner Haas
Vice President Operations
+49 (0) 6221 454 812
franz-werner.haas@sygnis.de

Media-Contact:
Julia Phillips
Financial Dynamics
Tel.: +44 (0) 20 7269 7187

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade

Plus de actualités: SYGNIS AG
Plus de actualités: SYGNIS AG
  • 12.08.2010 – 08:31

    EANS-News: SYGNIS announces three months results of fiscal year 2010/2011

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. 3-month report Heidelberg (euro adhoc) - Press release Heidelberg, August 12, 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports financial results for the first quarter of the fiscal ...

  • 29.06.2010 – 08:37

    EANS-News: SYGNIS announces Financial Results for fiscal year 2009/2010

    Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. annual report Heidelberg (euro adhoc) - Heidelberg, 29 June 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced its financial results for the 2009/2010 fiscal year, which ended on 31 March ...

  • 11.02.2010 – 09:39

    SYGNIS announces nine months results of fiscal year 2009/2010

    Heidelberg (ots) - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports financial results for the third quarter and the first nine months of the fiscal year 2009/2010 ended December 31, 2009. Financials - Cash including marketable securities amounted to EUR16.4 million as of December 31, 2009 (EUR26.0 million Q3 2008/2009). Long term financial liabilities ...